Evidence map›Paper›PMID 24021498›Full record

Trial reportThe Journal of clinical psychiatry2013

Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.

Paul B Rosenberg, Krista L Lanctôt, Lea T Drye, Nathan Herrmann, Roberta W Scherer, David L Bachman, Jacobo E Mintzer, ADMET Investigators

2 registry-linked trialsAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 102 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 9 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01117181 phase2completednot on this map

Apathy in Dementia Methylphenidate Trial (ADMET)

TypeinterventionalSponsorJohns Hopkins Bloomberg School of Public HealthRan2010 to 2012Enrolled60ConditionsApathy, Alzheimer's DiseaseArmsMethylphenidate, placebo, Psychosocial intervention
NCT05669170 phase2not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Evaluating Safety and Potential Benefit of Methylphenidate as a Symptomatic Treatment for Apathy in Veterans With Parkinson's Disease.

TypeinterventionalSponsorRalph H. Johnson VA Medical CenterRan2024 to 2028Enrolled60ConditionsParkinson Disease, ApathyArmsPsychosocial intervention, Methylphenidate
3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 9 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Apathy Associated with Alzheimer's Disease.Current Alzheimer research · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pharmacological interventions for apathy in Alzheimer's disease.The Cochrane database of systematic reviews · 2018
    Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Loss of neuronal population organization links pathology to behavior in a model of Alzheimer's disease.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Paul B RosenbergDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine.
Krista L Lanctôt
Lea T Drye
Nathan Herrmann
Roberta W Scherer
David L Bachman
Jacobo E Mintzer
ADMET Investigators
Johns Hopkins University · USMedical University of South Carolina · USUniversity of Toronto · CABehavioral Pharma (United States) · US

Funding

'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI LYKETSOS, CONSTANTINE G · 1985 to 2019
$37.6M
DIADS-3: An RCT of venlafaxine for depression in ADR01AG039384 · NIA · JOHNS HOPKINS UNIVERSITY · PI ROSENBERG, PAUL B · 2011 to 2013
$1.6M
Apathy in Alzheimer's Disease Methylphenidate TrialR01AG033032 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI LANCTOT, KRISTA L., MINTZER, JACOBO · 2009 to 2010
$1.4M
PET imaging of activated microglia in Alzheimer's DiseaseK08AG029157 · NIA · JOHNS HOPKINS UNIVERSITY · PI ROSENBERG, PAUL B · 2008 to 2012
$539k
NIA NIH HHS 1 K08 AG029157-01A1NIA NIH HHS K08 AG029157NIA NIH HHS P50 AG005146NIA NIH HHS R01 AG033032NIA NIH HHS R01 AG033032-01NIA NIH HHS R01 AG039384
6 · The paper itself

Abstract

objectiveIn a recent crossover trial, methylphenidate treatment decreased apathy in Alzheimer's disease. We further assessed this finding in the Apathy in Dementia Methylphenidate Trial (ADMET).

methodSix-week, randomized, double-blind, placebo-controlled multicenter trial enrolling Alzheimer's disease participants (NINCDS-ADRDA criteria) with apathy assigned to methylphenidate 20 mg daily or placebo, conducted from June 2010 to December 2011. Primary outcomes were change in Apathy Evaluation Scale (AES) score and modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGI-C). Secondary outcomes included change in Neuropsychiatric Inventory (NPI) apathy score, Mini-Mental State Examination (MMSE) score, and safety.

results60 participants were randomly assigned (29 methylphenidate, 31 placebo). At baseline, mean (SD) age = 76 (8) years, MMSE score = 20 (5), AES score = 51 (12), NPI total score = 16 (8), and 62% of the participants (n = 37) were female. After 6 weeks' treatment, mean (SD) change in AES score was -1.9 (1.5) for methylphenidate and 0.6 (1.4) for placebo (P = .23). Odds ratio for improvement in ADCS-CGI-C was 3.7 (95% CI, 1.3 to 10.8) (P = .02), with 21% of methylphenidate versus 3% of placebo rated as moderately or markedly improved. NPI apathy score improvement was 1.8 points (95% CI, 0.3 to 3.4) greater on methylphenidate than on placebo (P = .02). MMSE trended toward improvement on methylphenidate (P = .06). There were trends toward greater anxiety and weight loss > 2% in the methylphenidate-treated group.

conclusionsMethylphenidate treatment of apathy in Alzheimer's disease was associated with significant improvement in 2 of 3 efficacy outcomes and a trend toward improved global cognition with minimal adverse events, supporting the safety and efficacy of methylphenidate treatment for apathy in Alzheimer's disease.

trial registrationClinicalTrials.gov identifier: NCT01117181.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseApathyBenzhydryl CompoundsCentral Nervous System StimulantsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHumansMaleMethylphenidateModafinilNeuropsychological TestsPsychometricsBenzhydryl CompoundsCentral Nervous System StimulantsMethylphenidateModafinil

Identifiers

PMID24021498
PMCPMC3902018
OpenAlexW2030994918

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.